Navigation Links
Virus infection supports organ acceptance

This news release is available in German.

Over 150 million people throughout the world suffer from chronic infection with the hepatitis C virus (HCV), which causes massive damage to the liver. Advanced liver diseases often necessitate liver transplants. In the new clinical study Dr. Felix Bohne and his colleagues studied together with Prof. Alberto Snchez-Fueyo from King's College London 34 hepatitis C patients at the Liver Unit of the University Hospital Clnic de Barcelona who had received new livers.

The researchers had two objectives here: first, they wanted to gain a better understanding of the mechanisms that enable the body's own immune system to tolerate the new organ despite the HCV infection; second, they were looking for factors that could act as biomarkers for tolerance in the patients.

"If tolerance could be reliably predicted based on certain markers, many patients could stop taking immunosuppressants after a certain period of time," explains Dr. Felix Bohne, lead scientist of the study. Patients must take these strong drugs after transplants. They suppress the immune system so that the body does not identify the new organ as foreign and reject it. For patients with hepatitis C, this is a particular burden, as they need a stable immune system after the transplant to control their chronic HCV infection.

Markers for tolerance

During the study, the patients stopped taking the immunosuppressants. They were observed for twelve months to see which of them could also tolerate the new organ without the drugs, and which of them did not. The scientists took liver and blood samples from the patients prior to and after the cessation of the drugs. Detailed immunological tests on these patient samples were carried out under the leadership of Prof. Ulrike Protzer of the "Immunmonitoring Platform" at the Institute of Virology. The scientists compared the patients with each other and looked for any differences that arose in tolerant patients only.

And the scientists struck gold: a certain group of genes was very active only in the livers of tolerant patients. The genes in question belonged to the type I interferon system, which targets viruses like HCV as part of the innate immune system. As the results showed, an anti-viral mechanism does actually enable the patients to better tolerate a foreign organ.

Ulrike Protzer provides a possible explanation for this: "When the interferon system is constantly activated as is the case in some chronically-infected patients, it downregulates other immune reactions in order to protect the body. This state could act like a natural immunosuppressant and reduce the rejection of the organ."

In addition to the genes of the type I interferon system, a second factor was considered as a possible marker. This was discovered by the researchers in a previous study on liver recipients who did not have a HCV infection. Patients were very likely to be tolerant if they had a certain ratio of two different subgroups of immune cells in their blood. This ratio was also a reliable predictor of tolerance in the new study involving HCV patients.


Contact: Vera Siegler
Technische Universitaet Muenchen

Related biology news :

1. Studies reveal structure of EV71, a virus causing childhood illnesses
2. Discovery provides blueprint for new drugs that can inhibit hepatitis C virus
3. To drive infections, a hijacking virus mimics a cells signaling system
4. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
5. Harmless human virus may be able to boost the effects of chemotherapy
6. Researchers identify Achilles heel of dengue virus, target for future vaccines
7. Recapitulation of the entire hepatitis C virus life in engineered mouse cell lines
8. BGI, GMU, Mass. Eye and Ear and OUHSC announce agreement to sequence 100 human adenoviruses
9. Berkeley Lab scientists generate electricity from viruses
10. Virus barcodes offer rapid detection of mutated strains
11. Army study: DNA vaccine and duck eggs protect against hantavirus disease
Post Your Comments:
(Date:6/9/2016)... in attendance control systems is proud to announce the introduction of fingerprint attendance control ... right employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight Medical ... to the healthcare market. The company's primary focus is on new product introductions, ... strategies that are necessary to help companies efficiently bring their products to market. ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
Breaking Biology Technology: